Celcuity Inc. (CELC) stock intrinsic value fair value estimate & owner earnings analysis

Celcuity is a clinical-stage cancer drug developer with a single lead drug, gedatolisib, a PI3K/mTOR inhibitor licensed from Pfizer in April 2021 for worldwide development and sale. It has never had revenue. Its Phase 3 VIKTORIA-1 trial supported a new drug application for HR+/HER2- advanced breast cancer, which the FDA accepted on January 16, 2026 with priority review and a target decision date of July 17, 2026. The company said that, if approved, it expected sales to begin in the second half of 2026. Our valuation rests on cash the business actually generates for its owners after stock compensation, working capital swings and required investment. On that basis Celcuity has lost money every year we could measure: about $(1.79) per share in 2021, $(2.56) in 2022, $(2.65) in 2023, $(2.76) in 2024 and $(3.68) in 2025. Operating cash burn rose from $83 million in 2024 to $153 million in 2025, and stock compensation rose from $7 million to $21 million. Net loss in 2025 was $177 million. Bear, base and bull cases are each valued at $0 per share. We only credit value that is contracted, already earned or the output of a repeatable track record. Gedatolisib's approval, launch pace, pricing, physician adoption and share against existing breast cancer treatments are all events that had not happened as of the latest annual report we used, so none can be counted, even though trial data and the priority review are encouraging. Because no earnings history exists to project, no case is built on hoped-for future sales. If approval and a profitable launch occur, the shares would then be worth something, and this analysis would need to be redone from actual results. We do not treat a positive FDA outcome as already priced in to this estimate. The company ended 2025 with $441.5 million of cash and short-term investments against $338.8 million of principal debt, of which $130.0 million is secured term loans and $201.3 million is convertible notes issued in August 2025. The notes could convert into about 3.9 million shares, which would dilute current holders. Management stated the cash is sufficient to fund operations for at least one year. Following our approach, we neither add the cash nor subtract the debt; cash burn and interest already reduce the owner earnings figure, and the funding needs and dilution are the main reasons the downside is real. What would make this wrong: a rapid, well-priced launch that converts the drug into a large stream of profitable sales. That is possible, but until sales exist it cannot be underwritten from the filings. The margin-of-safety price is therefore $0, and the estimate would be revisited only after approval and several periods of real, profitable results.